AI summary · may contain errors
Dupilumab treatment in eosinophilic chronic rhinosinusitis is linked to broad transcriptional remodeling in nasal polyp myeloid cells, especially cDCs, with ALOX15 downregulation.
- Open access
Moving in Journal of Allergy and Clinical Immunology, American Journal of Respiratory and Critical Care Medicine, The Lancet Respiratory Medicine, Cellular & Molecular Immunology, Clinical Infectious Diseases, European Respiratory Journal and Ophthalmology.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
Dupilumab treatment in eosinophilic chronic rhinosinusitis is linked to broad transcriptional remodeling in nasal polyp myeloid cells, especially cDCs, with ALOX15 downregulation.
AI summary · may contain errors
Dupilumab improved sinus opacification on Lund-Mackay computed tomography at week 52 in patients with allergic fungal rhinosinusitis, with an LSMD of -7.36 versus placebo.
AI summary · may contain errors
In 621 Italian patients with severe, uncontrolled CRSwNP treated with mepolizumab 100 mg every 4 weeks, nasal polyp and SNOT-22 scores significantly decreased by 12 months (p<0·0001).
AI summary · may contain errors
In nasal polyp tissue from 91 CRSwNP patients, 23 inflammatory mediators predicted rapid post-FESS recurrence, with type 2 and innate/myeloid markers linked to AUC > 0.70.
AI summary · may contain errors
In human eCRS nasal polyps, a TGM2hi macrophage population is enriched in inflamed tissue and strongly correlated with local eosinophilia and systemic disease burden.
Journals this month
Topics moving, week to 17 Nov 2026
By field